As Baxter Embarks On A New Course, It Bolsters Its Hemophilia Franchise
This article was originally published in The Pink Sheet Daily
While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.
You may also be interested in...
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
Amarin signed Kowa Pharmaceuticals America as a commercial partner for its fish oil pill, more than doubling the number of sales reps detailing the medicine. Forma signed a second drug discovery pact with Celgene, while Baxter bolstered its hemophilia franchise by buying out partner Chatham Therapeutics.